DOCSLIB.ORG

Interlude of Cgmp and Cgmp/Protein Kinase G Type 1 in Pancreatic Adenocarcinoma Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interlude of Cgmp and Cgmp/Protein Kinase G Type 1 in Pancreatic Adenocarcinoma Cells ORIGINAL ARTICLE Interlude of cGMP and cGMP/Protein Kinase G Type 1 in Pancreatic Adenocarcinoma Cells Svetlana Karakhanova, PhD,* Marina Golovastova, MS,Þ Pavel P. Philippov, PhD,Þ Jens Werner, MD,* and Alexandr V. Bazhin, PhD* whereas the expression of PKG2 is generally restricted to the Objective: cAMP and cGMP signaling is important both for normal brain, intestine, and kidneys. The PKG1 is more commonly acti- and cancer cells. This signaling is controlled by adenylyl and guanylyl vated when cGMP signaling is mediated by nitric oxide (NO).3 cyclases and cyclic nucleotide phosphodiesterases. One of the direct The NO at nanomolar concentration binds to haem, a prosthetic targets for cGMP is protein kinase G (PKG). The main aim of this work group of soluble GC, and causes a 100- to 200-fold activation was to investigate cGMP and PKG signaling in pancreatic adenocarci- of the enzyme.4 Activation of NO-GC increases conversion of noma (PDAC) cells. GTP to cGMP, resulting in the elevation of cGMP, which ini- Methods: The PKG activity, cGMP, and calcium level were measured tiates the cGMP signaling pathway and subsequent physiologic with the CycLex Cyclic GMP dependent protein kinase (cGK) Assay Kit, changes.5 These physiologic changes, such as the relaxation of the DetectX Cyclic GMP Colorimetric EIA Kit, and the Fluo-4 NW Cal- the vascular and gastrointestinal smooth muscles, the inhibi- cium Assay Kit, respectively. The Proteome Profiler Array was done using tion of platelet aggregation, and other processes, are medi- Human Phospho-Kinase Array and Human Phospho-MAPK Array Kits. ated through the phosphorylation of specific targets of PKG3 Results: This study shows for the first time that functional PKG1 is (Fig. S1, http://links.lww.com/MPA/A301). Furthermore, PKG1 expressed in PDAC cells. It demonstrates that the specific PKG1 inhibitor, signaling could be involved in cytoprotection through different DT3, induces cytotoxicity through necrosis and reduces proliferation and mechanisms. Such cytoprotective effects have been observed migration of PDAC cells. Moreover, ERK1/2 and p38 can be considered as in heart cells, neurons and glia, and epithelial cells, which are potential targets for PKG1 in PDAC cells. In addition, the study shows that probably mediated through an increase in the opening of mito- phosphodiesterases and nitric oxide-guanylyl cyclases regulate the cGMP chondrial K+/ATP channels in heart cells, activating extracellular- level in PDAC cells, affecting the proliferation of the cells. signal regulated kinase (ERK) signaling, and Bcl-2-associated Conclusions: The cGMP and PKG signaling may be a target for de- death promoter (BAD) protein phosphorylation.3 veloping new therapeutic approaches for PDAC. The elevation of cGMP and activation of PKG1 promote Key Words: pancreatic adenocarcinoma, protein kinase G, guanylyl apoptosis in colon cancer.6 The investigators claim that PKG1 cyclases, cyclic nucleotide phosphodiesterases, cGMP activation in colon cancer cells results in phosphorylation and Y activation of the mitogen-activated protein kinase kinase (Pancreas 2014;43: 784 794) (MEKK1), activation of the stress-activated protein/ERK kinase 1 (SEK1), and activation of the c-Jun NH2-terminal kinase 1 (JNK1) pathway. Recently, it has been demonstrated that the ntracellular signaling, as a complicated regulatory network, plays basal activity of PKG is essential for preventing spontaneous Ia major role during normal and pathologic cell responses. The apoptosis.7 These data are in contrast with the proposed cAMP and cGMP were the first molecules to be described as sec- antiproliferative effect of PKG mentioned previously. Fraser et al ond messengers.1 Their levels are controlled during their synthesis speculated that, in colon cancer cell lines, the growth-inhibitory by adenylyl and guanylyl cyclases (GC) and through the activation responses were initiated by either overexpression of PKG (espe- of cyclic nucleotide phosphodiesterases (PDEs). The cAMP and cially the PKG1A isoform) or the elevation of PKG1A activity cGMP regulate multiple intracellular targets (eg, protein kinases A (but not the basal PKG activity). Thus, there is growing evidence and G), cyclic nucleotide-gated channels, and PDEs themselves. that the different isoforms of PKG1 may regulate cell proliferation One of the direct targets of cGMP is protein kinase G in different ways: PKG1> activity (especially at the basal level) (PKG).2 The 2 PKG (sub)families (PKG1 and PKG2) are derived promotes cell proliferation, whereas PKG1A (overexpressed or from separate genes. The PKG1 family consists of 2 isoforms hyperactivated) inhibits cell proliferation. PKG1> and PKG1A.ThePKG1 isoforms are widely distributed, Taken together, there is generally only poor and contra- dicting information on the phenotypical effects of activation/ inhibition of PKG and their underlying molecular mechanisms in cancer cells. In addition, there are no data on the expression, From the *Department of General Surgery, University Hospital Heidelberg, function, and effect of inhibition/activation of PKG in pancreatic Germany; and †Department of Cell Signalling, Belozersky Institute of Physico- Chemical Biology, Lomonosov Moscow State University, Moscow, Russia. carcinoma cells. Received for publication May 7, 2013; accepted January 14, 2014. Pancreatic ductal adenocarcinoma (PDAC) is one of the Reprints: Alexandr V.Bazhin, PhD, Department of General Surgery, University deadliest cancers in the world. The PDAC mortality increases Hospital Heidelberg, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany modestly in countries of the southern and central/eastern (e<mail: [email protected]). 8 This study was supported by a grant from Wilhelm Sander-Stiftung Europe, as well as in women. Patients with PDAC have a very (2011.036.1) to A.V. B. and J.W. and by the grant from the Russian poor prognosis with a 5-year survival rate of less than 1% and a Foundation for Basic Research (#12-04-00922) to P.P.P. median survival of 6 months.9 Even after surgical intervention, The authors declare no conflict of interest. the 5-year survival rate is reached at best 15% without or 25% Supplemental digital contents are available for this article. Direct URL citations 10 appear in the printed text and are provided in the HTML and PDF versions of with adjuvant chemotherapy in specialized centers. The rea- this article on the journal’s Web site (www.pancreasjournal.com). sons for this poor prognosis are its early dissemination, lack of Copyright * 2014 by Lippincott Williams & Wilkins early specific symptoms, and late diagnosis.11 In addition, 784 www.pancreasjournal.com Pancreas & Volume 43, Number 5, July 2014 Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Pancreas & Volume 43, Number 5, July 2014 PKG1 in Pancreatic Cancer (HPNPCC) was obtained from Celprogen, and the cells were TABLE 1. Expression of PKG and Their Activity in Pancreatic cultivated in the HPNPCC complete growth media with serum Malignant and Benign Cell Lines provided by the manufacturer. Cell lines were cultivated at 37-C and 5% of carbon dioxide. Cells were routinely checked mRNA Protein IC50 for for mycoplasma contamination and commercially authenticat- Cell Lines PKG1 PKG2 PKG1 Activity, u/mg DT3, KM ed by Multiplexon GmbH (Germany). BXPC3 + j + 0.91 T 0.15 n.d. Capan-1 + j +1T 0.3 0.5625 RNA Isolation and Reverse Transcription Dan-G + j + 0.5 T 0.1 n.d. Polymerase Chain Reaction Analysis MiaPaCa + j + 0.8 T 0.05 1.782 Total RNA from cell lines was isolated using an RNeasy Panc1 + jj0.007 T 0.001 n.d. mini kit (Qiagen, Germany) according to the manufacturer’s ACBRI515 + jj u.d.l. n.d. instructions. The RNA concentrations were determined using a HPNPCC + jj u.d.l. n.d. NanoPhotometer Pearl (SERVA Electrophoresis, Germany). The reverse transcription polymerase chain reaction (RT-PCR) n.d. indicates no data; u.d.l., under detection limit. analysis of PKG1 and PKG2 was performed as previously de- scribed by Sengene`s et al.12 Briefly, 1 Kg of the total RNA from PDAC is highly resistant to chemotherapy and targeted therapy. cell lines or tissues was reverse-transcribed by using the first It is for this reason that new therapeutic strategies are urgently strand cDNA synthesis kit (Roche Diagnostics, Germany) at needed. In this work, the roles of cGMP and PKG1 in PDAC 42-C for 50 minutes, as described by the manufacturer. The cells are investigated. PCR amplification was performed using 1 Kl from the RT- reaction mixture in 25 Kl of the PCR mixture containing 50 MATERIALS AND METHODS pmol of sense and antisense primers. After the initial incubation at 94-C for 2 minutes, 33 cycles of amplification were carried out Materials for PKG1 and PKG2 as well as special isoforms of GC and PDE The membrane-permeant peptide-based inhibitor of (Table 2) and 21 cycles for glyceraldehyde 3-phosphate dehy- PKG1>VDT3Vwas purchased from BIOLOG Life Sci- drogenase (GAPDH). At least 3 independent PCR experiments ence Institute (Germany). The soluble GCs inhibitor 1H- were running. Primer sequences annealing temperatures and sizes [1,2,4]oxodiazolo[4,3-a]quinoxalin-1-one (ODQ) and the NO of PCR products for the PKG1 and PKG2 were published by donor 4-ethyl-2E-(hydroxyimino)-5-nitro-3E-hexenamide (FK- Sengene`setal.12 The same parameters for GAPDH were pub- 409) were obtained from Cayman Chemical. The endogenous lished previously by us.13 The RT-PCR primers for GC and PDE peptide activator of intestinal GCVguanylinVwas purchased were purchased from Qiagen (Germany). from TOCRIS Bioscience (United Kingdom). Carbachol (carbamoylcholine chloride) was purchased from Sigma-Aldrich (Germany). A goat polyclonal (monospecific) antibody against Western Blot Analysis PKG1>/A was purchased from Santa Cruz Biotechnology, Inc. Western blot analysis was performed as described else- 13 K Antibodies against phosphorylated and unphosphorylated forms where. Briefly, 10 g of total protein per lane were separated of CREB, ERK1/2, GSK-3, JNK, and P38 were purchased from in 12.5% of polyacrylamide gel.
Load more

Recommended publications
  • Dissertation Characterization Of
    DISSERTATION CHARACTERIZATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES IN THE TRANSCRIPTOME OF THE CRUSTACEAN MOLTING GLAND Submitted by Nada Mukhtar Rifai Department of Biology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Spring 2019 Doctoral Committee: Advisor: Donald L. Mykles Deborah Garrity Shane Kanatous Santiago Di-Pietro Copyright by Nada Mukhtar Rifai 2019 All Rights Reserved ABSTRACT CHARACTERIZATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES IN THE TRANSCRIPTOME OF THE CRUSTACEAN MOLTING GLAND Molting in crustaceans is a complex physiological process that has to occur in order for the animal to grow. The old exoskeleton must be discarded and a new one to be formed from the inside out. Molting is coordinated and regulated mainly by two hormones; steroid hormones named ecdysteroids, which are synthesized and secreted from a pair of Y- organs (YOs) that are located in the cephalothorax and a neuropeptide hormone, the molt inhibiting hormone (MIH), which is secreted from the X-organ/sinus gland complex located in the eyestalks. Molting is induced when MIH is decreased in the blood (hemolymph) which in turn stimulates the YOs to produce and secrete ecdysteroids (molting hormones). There are four distinctive physiological states that the YO can be in throughout the molt cycle; the transition of the YO from the “basal” to the “activated” state happens when the animal enters premolt. During mid-premolt, the YO transitions to the “committed” state, in which the YO becomes insensitive to MIH. In this state, the circulating hemolymph contains high levels of ecdysteroids, which increase to a peak before the actual molt (ecdysis) happens.
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • A Novel, Highly Potent and Selective Phosphodiesterase-9 Inhibitor for the Ferrata Storti Foundation Treatment of Sickle Cell Disease
    Red Cell Biology & its Disorders ARTICLE A novel, highly potent and selective phosphodiesterase-9 inhibitor for the Ferrata Storti Foundation treatment of sickle cell disease James G. McArthur,1 Niels Svenstrup,2 Chunsheng Chen,3 Aurelie Fricot,4 Caroline Carvalho,4 Julia Nguyen,3 Phong Nguyen,3 Anna Parachikova,2 Fuad Abdulla,3 Gregory M. Vercellotti,3 Olivier Hermine,4 Dave Edwards,5 Jean-Antoine Ribeil,6 John D. Belcher3 and Thiago T. Maciel4 1Imara Inc., 2nd Floor, 700 Technology Square, Cambridge, MA, USA; 2H. Lundbeck A/S, 3 Haematologica 2020 Ottiliavej 9, 2500 Valby, Denmark; Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; Volume 105(3):623-631 4INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Laboratory of Excellence GR-Ex, Paris Descartes - Sorbonne Paris Cité University, Paris, France; 5Kinexum, 8830 Glen Ferry Drive, Johns Creek, GA, USA and 6Departments of Biotherapy, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes- Sorbonne Paris Cité University, Paris, France ABSTRACT he most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with Tpleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium. Hydroxyurea has been proposed to mediate these effects through a mechanism of increasing cellular cGMP levels. An alternative path to increasing cGMP levels in these cells is through the use of phospho- diesterase-9 inhibitors that selectively inhibit cGMP hydrolysis and increase cellular cGMP levels. We have developed a novel, potent and selective phosphodiesterase-9 inhibitor (IMR-687) specifically for the treatment of Correspondence: SCD.
    [Show full text]
  • Chemical Genetic Studies of Chemical Modulators of Mammalian Adenylyl Cyclases and Phosphodiesterases Expressed in Fission Yeast
    Chemical Genetic Studies of Chemical Modulators of Mammalian Adenylyl Cyclases and Phosphodiesterases Expressed in Fission Yeast Author: Ana Santos de Medeiros Persistent link: http://hdl.handle.net/2345/bc-ir:106786 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2016 Copyright is held by the author, with all rights reserved, unless otherwise noted. Boston College Morrisey College of Arts and Sciences Graduate School Department of Biology CHEMICAL GENETIC STUDIES OF CHEMICAL MODULATORS OF MAMMALIAN ADENYLYL CYCLASES AND PHOSPHODIESTERASES EXPRESSED IN FISSION YEAST a dissertation by ANA SANTOS DE MEDEIROS Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy May 2016 © copyright by ANA SANTOS DE MEDEIROS 2016 ABSTRACT Cyclic adenosine monophosphate (cAMP) and the second messengers that modulate several biological processes are regulated by adenylyl cyclase (AC) and cyclic nucleotide phosphodiesterases (PDEs). ACs and PDEs are comprised of superfamilies of enzymes that are viewed as druggable targets due to their many distinct biological roles and tissue-specific distribution. As such, small molecule regulators of ACs and PDEs are important as chemical probes to study the roles of individual ACs or PDEs and as potential therapeutics. In the past, our lab has expressed 15 mammalian PDE genes in S. pombe, replacing the endogenous Cgs2 PDE. High throughput screens for PDE inhibitors identified novel compounds that show relevant biological activity in mammalian cell culture assays. The aim of this thesis is to develop tools to understand the mechanism of interaction between key regulators of the cAMP pathway and small molecules.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • 1 PDE5 Inhibition Improves Symptom-Free Survival and Restores
    bioRxiv preprint doi: https://doi.org/10.1101/248187; this version posted January 17, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. PDE5 inhibition improves symptom-free survival and restores transverse tubule loss and catecholamine responsiveness in heart failure 1 1 Michael Lawless , Jessica L. Caldwell , Emma J. Radcliffe, George W.P. Madders, David C. 2 2 Hutchings, Lori S. Woods, Stephanie J. Church , Richard D. Unwin , Graeme J. Kirkwood, Lorenz K. Becker, Charles M. Pearman, Rebecca F. Taylor, David A. Eisner, Katharine M. * Dibb & Andrew. W Trafford . 1. Contributed Equally * Correspondence 2. Unit of Cardiac Physiology and Centre for Advanced Discovery and Experimental Therapeutics, Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester Academic Health Science Centre, 3.24 Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT, United Kingdom. +44 161 275 7969 [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/248187; this version posted January 17, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Heart failure is characterized by poor survival, a loss of catecholamine reserve and cellular structural remodeling in the form of disorganization and loss of the transverse tubule network. Indeed, survival rates for heart failure are worse than many common cancers and have not improved over time.
    [Show full text]
  • Characterization of the First Potent and Selective PDE9 Inhibitor Using A
    Molecular Pharmacology Fast Forward. Published on September 8, 2005 as DOI: 10.1124/mol.105.017608 Molecular PharmacologyThis article Fasthas not Forward. been copyedited Published and formatted. on TheSeptember final version 8,may 2005 differ asfrom doi:10.1124/mol.105.017608 this version. MOL 17608 Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line Frank Wunder, Adrian Tersteegen, Annegret Rebmann, Christina Erb, Thomas Fahrig, and Martin Hendrix Downloaded from molpharm.aspetjournals.org Cardiovascular Research (F.W., A.R.), Molecular Screening Technology (A.T.), CNS Research (C.E., T.F.) and Medicinal Chemistry (M.H.), Bayer HealthCare AG, Aprather Weg 18a, D-42096 Wuppertal, Germany at ASPET Journals on September 23, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on September 8, 2005 as DOI: 10.1124/mol.105.017608 This article has not been copyedited and formatted. The final version may differ from this version. MOL 17608 Running title: Characterization of the first selective PDE9 inhibitor Corresponding author: Dr. Frank Wunder Bayer HealthCare AG Cardiovascular Research Aprather Weg 18a D-42096 Wuppertal, Germany Downloaded from PHONE: ++ 49-202-364107 FAX: ++ 49-202-368009 E-MAIL: [email protected] molpharm.aspetjournals.org Number of text pages: 28 Number of tables: 1 Number of figures: 6 at ASPET Journals on September 23, 2021 Number of references: 26 Number of words in the abstract: 232 Number of words in the introduction: 658 Number of words in the discussion: 1407 Abbreviations: cGMP, guanosine 3'-5'-cyclic monophosphate; CNG, cyclic nucleotide-gated; IBMX, 3-isobutyl-1-methylxanthin; MTP, microtiter plate; NO, nitric oxide; PDE, cyclic nucleotide-specific phosphodiesterase; RLU, relative light unit; sGC, soluble guanylate cyclase; uHTS, ultra-high-throughput screening 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond
    International Journal of Molecular Sciences Review Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond Tatiana M. Vinogradova * and Edward G. Lakatta Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, National Institute of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA; [email protected] * Correspondence: [email protected] Abstract: The sinoatrial (SA) node is the physiological pacemaker of the heart, and resting heart rate in humans is a well-known risk factor for cardiovascular disease and mortality. Consequently, the mechanisms of initiating and regulating the normal spontaneous SA node beating rate are of vital importance. Spontaneous firing of the SA node is generated within sinoatrial nodal cells (SANC), which is regulated by the coupled-clock pacemaker system. Normal spontaneous beating of SANC is driven by a high level of cAMP-mediated PKA-dependent protein phosphorylation, which rely on the balance between high basal cAMP production by adenylyl cyclases and high basal cAMP degradation by cyclic nucleotide phosphodiesterases (PDEs). This diverse class of enzymes includes 11 families and PDE3 and PDE4 families dominate in both the SA node and cardiac myocardium, degrading cAMP and, consequently, regulating basal cardiac pacemaker function and excitation-contraction coupling. In this review, we will demonstrate similarities between expression, distribution, and colocalization of various PDE subtypes in SANC and cardiac myocytes of different species, including humans, focusing on PDE3 and PDE4. Here, we will describe specific targets of the coupled-clock pacemaker system modulated by dual PDE3 + PDE4 activation and provide Citation: Vinogradova, T.M.; Lakatta, evidence that concurrent activation of PDE3 + PDE4, operating in a synergistic manner, regulates the E.G.
    [Show full text]
  • Cardioprotection by Bioactive Polyphenols: a Strategic View
    Open Access Austin Journal of Cardiovascular Disease and Atherosclerosis Review Article Cardioprotection by Bioactive Polyphenols: A Strategic View Chu AJ* Department of Surgery, School of Medicine, Wayne State Abstract University, Detroit, USA Cardiovascular disease (CVD) remains one causing most mortality *Corresponding author: Arthur J. Chu, Department worldwide. Common CVD risks include oxidative stress, hyperlipidemia, of Surgery, School of Medicine, Wayne State University, endothelial dysfunction, thrombosis, hypertension, hyperhomocysteinemia, Detroit, USA inflammation, diabetes, obesity, physical inactivity, and genetic factors. Among which, lifestyle changes including diets are modifiable CVD risks, becoming Received: February 15, 2018; Accepted: March 23, the first line of prevention prior to any medication. In the past decades, the 2018; Published: March 30, 2018 USDA, the American Heart Association, the American Nutrition Association, the Academy of Nutrition and Dietetics, and many other health organizations have launched five colors daily with vegetable and fruit consumption for human health. Lipophilic polyphenols, phytochemicals rich in vegetables and fruits, show classical antioxidation (e.g., radical-scavenging, metal chelating, NOX inhibition, attenuation on mitochondrial respiration, inhibition on xanthine oxidase, and upregulations on endogenous antioxidant enzymes), multiple effects on cell signaling (e.g., AMPK activation, SirT1 activation, eNOS activation, FOXO activation, NFkB inactivation, PI3K/AkT inhibition,
    [Show full text]
  • Full Text (PDF)
    Published OnlineFirst August 7, 2014; DOI: 10.1158/1535-7163.MCT-14-0172 Molecular Cancer Cancer Biology and Signal Transduction Therapeutics Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs Laurence Booth1, Jane L. Roberts1, Nichola Cruickshanks1, Steven Grant2, Andrew Poklepovic2, and Paul Dent1 Abstract The present studies examined the toxic interaction between the non-coxib celecoxib derivative OSU-03012 and phosphodiesterase 5 (PDE5) inhibitors, and also determined the roles of endoplasmic reticulum stress response regulators in cell survival. PDE5 inhibitors interacted in a greater than additive fashion with OSU- 03012 to kill parental glioma and stem-like glioma cells. Knockdown of the endoplasmic reticulum stress response proteins IRE1 or XBP1 enhanced the lethality of OSU-03012, and of [OSU-03012 þ PDE5 inhibitor] treatment. Pan-caspase and caspase-9 inhibition did not alter OSU-03012 lethality but did abolish enhanced killing in the absence of IRE1 or XBP1. Expression of the mitochondrial protective protein BCL-XL or the caspase-8 inhibitor c-FLIP-s, or knockdown of death receptor CD95 or the death receptor caspase-8 linker protein FADD, suppressed killing by [OSU-03012 þ PDE5 inhibitor] treatment. CD95 activation was blocked by the nitric oxide synthase inhibitor L-NAME. Knockdown of the autophagy regulatory proteins Beclin1 or ATG5 protected the cells from OSU-03012 and from [OSU-03012 þ PDE5 inhibitor] toxicity. Knockdown of IRE1 enhanced OSU-03012/[OSU-03012 þ PDE5 inhibitor]–induced JNK activation, and inhibition of JNK sup- pressed the elevated killing caused by IRE1 knockdown. Knockdown of CD95 blunted JNK activation.
    [Show full text]